Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies - Takeaways - MDSpire

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

  • By

  • Zhongfei Tao

  • Zuzana Chyra

  • Jana Kotulová

  • Piotr Celichowski

  • Jana Mihályová

  • Sandra Charvátová

  • Roman Hájek

  • December 3, 2024

  • 0 min

Share

  • 1

    CAR-T cell therapy has significantly advanced treatment for hematological malignancies, achieving high complete response rates in various B-cell cancers.

  • 2

    Despite high response rates, approximately 50% of patients experience disease progression within a year after CAR-T cell therapy.

  • 3

    T-cell characteristics, such as exhaustion and memory differentiation, critically influence the efficacy and safety of CAR-T cell therapy.

  • 4

    Exhausted T cells exhibit poor proliferation and high inhibitory receptor expression, which can negatively impact CAR-T therapy outcomes.

  • 5

    A diverse TCR repertoire and specific CAR-T cell ratios can enhance therapeutic responses and reduce toxicity in treated patients.

Original Source(s)

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

  • by Zhongfei Tao, Zuzana Chyra, Jana Kotulová, Piotr Celichowski, Jana Mihályová, Sandra Charvátová, Roman Hájek

  • December 3, 2024

Related Content

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence